// App-Quantinova.ai

P1140 : TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE

Researchers

Presenter

  • Frits van Rhee

Principal Investigators

  • Adam Rosenthal

  • Karan Kanhai

  • Rabecka Martin

  • Katherine Nishimura

  • Antje Hoering

  • David Fajgenbaum

Medical Centers

  • EUSA Pharma,Hemel Hempstead,Storbritannien

  • Cancer Research And Biostatistics,Seattle,Vereinigte Staaten

  • EUSA Pharma,Hemel Hempstead,Royaume-uni

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • University of Pennsylvania,Philadelphia, PA,Vereinigte Staaten

  • University of Pennsylvania,Philadelphia, PA,Estados Unidos

  • University of Pennsylvania,Philadelphia,Stati Uniti

  • EUSA Pharma, Hemel Hempsted, United Kingdom

  • University of Pennsylvania,Philadelphia,Stati Uniti

  • University of Arkansas for Medical Sciences,Little Rock,Vereinigte Staaten

  • EUSA Pharma,Hemel Hempstead,Reino Unido

  • Penn FTD Center, University of Pennsylvania Philadelphia PA United States

  • Can

  • Cancer Research And Biostatistics,Seattle,Estados Unidos

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • EUSA Pharma,Hemel Hempstead,Verenigd Koninkrijk

  • University of Pennsylvania,Philadelphia, PA,Vereinigte Staaten

  • Cancer Research And Biostatistics,Seattle,Vereinigte Staaten

  • EUSA Pharma,Hemel Hempstead,Vereinigtes Königreich

  • Cancer Research And Biostatistics,Seattle,Estados Unidos

  • University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • EUSA Pharma,Hemel Hempstead,Соединённое Королевство

  • Cancer Research And Biostatistics,Seattle,Vereinigte Staaten

  • EUSA Pharma,Hemel Hempstead,Reino Unido

  • University of Bern

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • Cancer Research And Biostatistics,Seattle,Estados Unidos

Locations

  • United States

  • United Kingdom

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

  • Oncology (ONC)

Disease

  • Kaposi's sarcoma

  • Castleman disease

  • Idiopathic multicentric Castleman’ s disease

Biomarkers

  • N/A

Drug/Treatment

  • Siltuximab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • NCT01024036

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved